Martin Haluzík is a Professor of Internal Medicine, Director of the Diabetes Centre of the Institute for Clinical and Experimental Medicine in Prague and Head of the Metabolic Research Group at the Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague. Professor Haluzík's main areas of clinical expertise include diabetology, obesitology and general internal medicine. The major focus of his research concerns the aetiopathogenesis of obesity, insulin resistance and type 2 and type 1 diabetes. Professor Haluzík has special interests in the endocrine function of adipose tissue, the incretin system, novel hormonal factors involved in the regulation of energy homeostasis and glucose metabolism, and the use of novel technologies and therapeutics in the treatment of diabetes. He has been a global expert panel member and national leader for numerous clinical trials with novel antidiabetic drugs including the HARMONY, the PIONEER 1, the LEADER, the SCORED and the SOUL trial. He is a Co-Editor in Chief of Journal of Endocrinology and Journal of Molecular Endocrinology and current member of the Scientific Board of EASD meeting 2023 in Hamburg. He has published over 250 papers in journals with IF. His current H-index is 48.
Get The Latest Updates